Last updated: February 19, 2026
Rivaroxaban, marketed as Xarelto, is an anticoagulant approved for preventing and treating thromboembolic events. Multiple suppliers manufacture and distribute rivaroxaban globally, including originators and generics.
Major Originator Manufacturers
| Company |
Headquarters |
Manufacturing Capabilities |
Notable Certifications |
Market Presence |
Approximate Launch Year |
| Bayer (Bayer Pharma) |
Germany |
Multiple sites globally |
FDA, EMA approvals |
Significant in North America, Europe, Asia |
2011 |
| Janssen Pharmaceuticals |
USA (subsidiary of J&J) |
U.S. and international sites |
FDA, EMA approvals |
Strong US and global market presence |
2011 |
Bayer's Role
Bayer developed rivaroxaban and initiated global commercialization. The Bayer manufacturing sites in Germany and the US produce the active pharmaceutical ingredient (API) and finished dosage forms.
Janssen's Role
Janssen distributes rivaroxaban in markets where Bayer does not hold exclusive rights. Both companies share supply responsibilities to meet global demand.
Generic Suppliers
Following patent expiration, multiple manufacturers introduced generic rivaroxaban. These suppliers have obtained approvals across various regions, particularly in low- and middle-income markets.
| Company |
Country of Origin |
Approvals (regulatory agency) |
Market Focus |
Entry Year (approximate) |
| Teva Pharmaceuticals |
Israel |
FDA, EMA, Brazil ANVISA, others |
North America, Europe, Latin America |
2017-2018 |
| Sun Pharmaceutical |
India |
FDA, EMA, others |
India, Southeast Asia, Africa |
2018 |
| Hikma Pharmaceuticals |
UK |
EMA, US (ANDA submission) |
Middle East, North Africa, Europe |
2019 |
| Mylan |
USA |
FDA, EMA |
North America, Europe, Asia |
2018 |
Regulatory Pathways
Most generics gained approval via Abbreviated New Drug Application (ANDA) pathways in the US. European approval occurred through the Centralized Procedure with EMA, or national agencies like MHRA in the UK.
API Suppliers
Active pharmaceutical ingredients for rivaroxaban are sourced from chemical suppliers in China and India. These ingredient suppliers offer high-volume API manufacturing and are critical to the generic supply chain.
| Supplier Name |
Country |
API Quality Certifications |
Market Role |
Capacity (kg/year) |
Notable Clients |
| Zhejiang Hisun Pharmaceutical |
China |
GMP, ISO 9001, ISO 14001 |
API manufacturing |
100+ metric tons |
Multiple generic makers |
| Hikal Ltd. |
India |
GMP, ISO 9001, ISO 14001 |
API manufacturing |
50+ metric tons |
Several generic companies |
Supply Chain Dynamics
The supply chain for rivaroxaban involves multiple tiers:
- API production predominantly in China and India.
- Intermediate processing in India, China, or manufacturing hubs in Europe and the US.
- Finished dosage manufacturing handled by Bayer, Janssen, and licensed generic producers.
Interoperability among these suppliers influences product availability, pricing, and regulatory compliance.
Regulatory and Patent Status
- Original patents expired in the US by 2018, facilitating generic entry.
- Some jurisdictions still protect patents, delaying generic approval.
- Data exclusivity periods vary by country, with some extending into early 2020s.
Regional Supplier Variations
| Region |
Key Suppliers and Market Players |
Notes |
| North America |
Bayer, Janssen, Teva, Mylan |
Bayer and Janssen dominate original market; generics are widely available post-2018 patent expiry |
| Europe |
Bayer, Janssen, Hikma, Teva |
Similar to North America with early generic entries |
| Asia-Pacific |
Sun Pharma, Hikal, local Chinese manufacturers |
Rapidly expanding generics market, API sourcing in China and India |
| Africa, Middle East |
Hikma, local manufacturers |
Distributors often source from Indian API producers |
Key Considerations for Stakeholders
- Supply security: Dependence on Chinese and Indian API manufacturers introduces geopolitical and supply chain risks.
- Regulatory landscape: Varying approval timelines impact market availability.
- Pricing dynamics: Generics significantly reduce costs; market entry depends on patent litigation and regulatory approvals.
Key Takeaways
- Bayer and Janssen are primary originators with robust worldwide manufacturing and distribution networks.
- Multiple generic manufacturers have entered markets since patent expirations around 2018, notably Teva, Mylan, Sun Pharma, and Hikma.
- API is primarily sourced from Chinese and Indian suppliers, with manufacturing capacities supporting global demand.
- Regulatory approvals vary by region, influencing supply chain flow.
- Ongoing patent protections in some markets sustain originator dominance and limit generic competition in certain jurisdictions.
FAQs
1. Who are the leading suppliers of rivaroxaban?
Bayer and Janssen are the original producers. Key generic suppliers include Teva, Mylan, Sun Pharma, and Hikma.
2. When did generic rivaroxaban enter the market?
Most generics entered between 2017 and 2018 after patent expiration in key markets like the US and Europe.
3. Where is the rivaroxaban API produced?
Primarily in China and India, with API manufacturing capacities in Zhejiang Hisun, Hikal Ltd., and other suppliers.
4. What regulatory hurdles exist for rivaroxaban supply?
Patent protections in some countries delay generics; regulatory approval timelines depend on local agencies' processes.
5. Are there regional differences in rivaroxaban supply?
Yes. Developed markets favor originator products; developing markets have more generic options due to earlier patent expiries and API exports.
References
[1] Food and Drug Administration (FDA). (2023). "Rivaroxaban (Xarelto) Drug Approvals."
[2] European Medicines Agency (EMA). (2022). "Authorization details for rivaroxaban."
[3] Bayer AG. (2021). "Annual Report."
[4] Janssen Pharmaceuticals. (2022). "Product Portfolio."
[5] Global Data. (2023). "Segment Analysis of Anticoagulant Market."
